Valneva SE (LON:0OB3)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 674.67M +51.3% |
| Revenue (ttm) | 152.37M +3.0% |
| Net Income | -100.49M |
| EPS | -0.60 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,036 |
| Average Volume | 48,624 |
| Open | 4.540 |
| Previous Close | 4.514 |
| Day's Range | 4.508 - 4.742 |
| 52-Week Range | 2.264 - 5.420 |
| Beta | 1.27 |
| RSI | 48.98 |
| Earnings Date | Mar 18, 2026 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2025, Valneva SE's revenue was 174.66 million, an increase of 3.00% compared to the previous year's 169.58 million. Losses were -115.19 million, 840.6% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Full Year 2025 Valneva SE Earnings Call Transcript
Full Year 2025 Valneva SE Earnings Call Transcript
Valneva (VALN) Partners with Elaris FlexCo for Vaccine Technology
Valneva (VALN) Partners with Elaris FlexCo for Vaccine Technology
Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday. Shares of Clearpoint Neuro Inc (NASDAQ: CLPT) fell sharply in pre-market trading after the co...
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program
VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive globa...
Earnings Scheduled For March 18, 2026
Companies Reporting Before The Bell • SailPoint (NASDAQ: SAIL) is estimated to report quarterly earnings at $0.08 per share on revenue of $292.61 million. • InspireMD (NASDAQ: NSPR) is expected to r...
Valneva Reports Audited FY25 Results Ahead Of Full Presentation Later Today
(RTTNews) - Valneva SE (VALN), a specialty vaccine company, reported its audited consolidated financial results for the full-year 2025, reaffirming its revenue performance and strengthened cash positi...
Valneva (VALN) Reports 3% Revenue Growth, Projects Lower 2026 Sales
Valneva (VALN) Reports 3% Revenue Growth, Projects Lower 2026 Sales
Valneva FY25 Net Loss Widens, Product Sales Down; Sees Lower Revenues In FY26
(RTTNews) - French biotech company Valneva SE (VALN, VLA.PA, VLA.VI) reported Wednesday wider net loss in fiscal 2025, mainly on the absence of prior year's gain and lower product sales.
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
Lyon (France), March 18, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its audited consolidated financial results for the year ended December 31, 2...
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
Lyon (France), March 9 , 202 6 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, M...
VALNEVA Declaration of shares and voting rights: February 28, 2026
VALNEVA Declaration of shares and voting rights February 28, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlo...
Valneva to Participate in Upcoming Investor Conferences
Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming inves...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results1 and pro...
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's sing...
VALNEVA Declaration of shares and voting rights: January 31, 2026
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon.
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical researc...
Valneva withdraws application for standard US approval of its chikungunya shot
French drugmaker Valneva said on Monday it has voluntarily withdrawn its application seeking standard approval of its chikungunya vaccine in the United States after the FDA suspended the shot's licens...
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
Saint Herblain (France), January 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company has decided to voluntarily withdraw the biolog...
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with e...
Valneva SE - Declaration of voting rights - December 2025
Registered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company t...
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Ph...
VALNEVA Declaration of shares and voting rights: November 30, 2025
Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France).
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.